WebPharmaceutical Manufacturing Company size 51-200 employees Headquarters South San Francisco, California Type Public Company Founded 2015 Locations Primary 101 Oyster Point Blvd Suite 300 South San... WebDisarm Therapeutics 4 years 4 months VP Chemistry Jan 2024 - Jun 20246 months Senior Director Molecular Discovery Mar 2024 - Dec 20243 years 10 months Cambridge, Massachusetts Research Fellow...
Disarm Therapeutics Drug Developments Pipeline Prospector
WebOct 15, 2024 · Disarm has discovered novel, potent SARM1 inhibitors and is advancing them in preclinical development, with the goal of delivering breakthrough treatments to … WebDisarm Therapeutics Preventing axonal degeneration in patients with neurological diseases Sold to Lilly (NYSE: LLY) Oct 2024 Avila Therapeutics Covalent irreversible inhibitors – Sold to Celgene (NASDAQ: CELG) Jan 2012 Vitae Pharmaceuticals Novel therapeutics using proprietary computational chemistry – Sold to Allergan (NYSE: AGN) … daily planet comics
Airway Therapeutics Completes Dose Escalation in Phase 1b Trial …
WebOur pipeline is purposely built to deliver transformative therapeutics for multiple diseases where enzyme approaches have not previously been considered. Our medicines are … WebJul 22, 2024 · Disarm is developing therapies that target axonal degeneration, which underlies a broad range of diseases of the central, ocular, and peripheral nervous systems. The company is developing drugs that inhibit SARM1, a protein that its scientific founders identified as a central driver of degeneration of axons. WebDec 23, 2024 · Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders, such as Alzheimer's disease,... daily planet cafe order online